Table 1.
demographic characteristics of the study sample (N=700)
| Variable | Specialty | P value* | ||
|---|---|---|---|---|
| Doctors 347 (49.6%) | Dentists 165 (23.6%) | Pharmacists 188 (26.9%) | ||
| Age n (%) | 0.127 | |||
| 20 – 29 years | 132 (47.8) | 71 (25.7) | 73 (26.4) | |
| 30 – 39 years | 166 (51.9) | 62 (19.4) | 92 (28.7) | |
| 40 years and older | 49 (47.1) | 32 (30.8) | 23 (22.1) | |
| Gender | 0.974 | |||
| Male | 69 (49.3) | 34 (24.3) | 37 (26.4) | |
| Female | 278 (49.6) | 131 (23.4) | 151 (27.0) | |
| Graduation level | 0.003 | |||
| Graduated | 266 (48.9) | 117 (21.5) | 161 (29.6) | |
| Postgraduates | 81 (51.9) | 48 (30.8) | 27 (17.3) | |
| Years of Experience | 0.012 | |||
| Less than 5 years | 139 (54.9) | 59 (23.3) | 55 (21.7) | |
| 5 – 9 years | 98 (50.0) | 37 (18.9) | 61 (31.1) | |
| 10 – 14 years | 63 (45.3) | 30 (21.6) | 46 (33.1) | |
| 15 – 19 years | 17 (34.7) | 19 (38.8) | 13 (26.5) | |
| 20 years and more | 30 (47.6) | 20 (31.7) | 13 (20.6) | |
| Vaccination status | 0.183 | |||
| First dose only | 67 (44.7) | 34 (22.7) | 49 (32.7) | |
| Two doses | 280 (50.9) | 131 (23.8) | 139 (25.3) | |
| Type of vaccine | 0.754 | |||
| Sinopharm | 67 (50.8) | 35 (26.5) | 30 (22.7) | |
| AstraZeneca | 80 (50.3) | 37 (23.3) | 42 (26.4) | |
| Pfizer | 200 (48.9) | 93 (22.7) | 116 (28.4) | |
| Symptoms | 0.329 | |||
| Yes | 240 (47.8) | 123 (24.5) | 139 (27.7) | |
| No | 107 (54.0) | 42 (21.2) | 49 (24.7) | |
| Onset of symptoms (n=526) | 0.764 | |||
| After 1st vaccine dose | 110 (48.0) | 54 (23.6) | 65 (28.4) | |
| After 2nd dose | 45 (42.9) | 27 (25.7) | 33 (31.4) | |
| After 1st and 2nd dose | 97 (50.5) | 46 (24.0) | 49 (25.5) | |
| History of previous infection | 0.254 | |||
| Infected | 168 (52.5) | 75 (23.4) | 77 (24.1) | |
| Not infected | 179 (47.1) | 90 (23.7) | 111 (29.2) | |
| Corticosteroid use (n=520) | 0.221 | |||
| Yes | 32 (59.3) | 9 (16.7) | 13 (24.1) | |
| No | 222 (47.6) | 119 (25.5) | 125 (26.8) | |
*
Chi-square test